Dosulepin hydrochloride

(Redirected from Dothiepin)
Jump to: navigation, search


Dosulepin hydrochloride
Dosulepin.svg
Clinical data
Pregnancy
category
  • C
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability30%
MetabolismHepatic
Elimination half-life20 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H21NS
Molar mass331.9 g/mol

Dosulepin hydrochloride (INN) (formerly the BAN dothiepin hydrochloride) is an antidepressant of the tricyclic family. It is sold under the brand names Prothiaden and Thaden.

Indications

Dosulepin is relatively mild and is used for low level anxiety depression and similar disorders, particularly where insomnia and/or loss of appetite are present. It can take between two and four weeks of regular usage to become effective, it is often started at a low level and the dosage increased if this is ineffective. The drug causes drowsiness as a side-effect, and this may be used as part of the treatment, since anxiety depressive patients may have difficulty sleeping, but it can be combined with other drugs such as temazepam.

Side effects

The most common side-effects are drowsiness and dry mouth. Other less common side-effects may include:

These side-effects cease when treatment ceases. Alcohol should be avoided whilst taking dosulepin as it may increase some side-effects.

Whilst dosulepin is not addictive, it should not be stopped suddenly as there is a risk of initial withdrawal symptoms which may be mistaken for some of the original indications for the drug:

  • Nausea
  • Vomiting
  • Loss of appetite
  • Headache
  • Giddiness
  • Chills
  • Insomnia
  • Anxiety

Contra-indications

Contra-indications include:

Drug interactions

The drug can interact dangerously with vasoconstrictors and should not be taken in combination with phenylephrine or adrenaline in particular.

This drug should not be started within 2 weeks of stopping a monoamine oxidase inhibitor (MAOI) antidepressant, and should not be co-administered with any selective serotonin reuptake inhibitor (SSRI) antidepressant such as fluoxetine), or any medication which affects the electrical impulses to the heart (e.g. astemizole, halofantrine or terfenadine).

The drug is not recommended for use by children nor taken in combination with some other drugs, including herbal remedies.

Overdose

The symptoms and the treatment of an overdose are largely the same as for the other tricyclic antidepressants.

See also


it:Dotiepina


Linked-in.jpg